Literature DB >> 34363676

Elevated Oxidative Stress and DNA Damage in Cortical Neurons of Chemotherapy Patients.

Matthew Torre1, Adwitia Dey1, Jared K Woods1, Mel B Feany1.   

Abstract

The unintended neurologic sequelae of chemotherapy contribute to significant patient morbidity. Chemotherapy-related cognitive impairment (CRCI) is observed in up to 80% of cancer patients treated with chemotherapy and involves multiple cognitive domains including executive functioning. The pathophysiology underlying CRCI and the neurotoxicity of chemotherapy is incompletely understood, but oxidative stress and DNA damage are highly plausible mechanisms based on preclinical data. Unfortunately, validating pathways relevant to CRCI in humans is limited by an absence of relevant neuropathologic studies of patient brain tissue. In the present study, we stained sections of frontal lobe autopsy tissue from cancer patients treated with chemotherapy (n = 15), cancer patients not treated with chemotherapy (n = 10), and patients without history of cancer (n = 10) for markers of oxidative stress (nitrotyrosine, 4-hydroxynonenal) and DNA damage (pH2AX, pATM). Cancer patients treated with chemotherapy had increased staining for markers of oxidative stress and DNA damage in frontal lobe cortical neurons compared to controls. We detected no statistically significant difference in oxidative stress and DNA damage by the duration between last administration of chemotherapy and death. The study highlights the potential relevance of oxidative stress and DNA damage in the pathophysiology of CRCI and the neurotoxicity of chemotherapy.
© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Cognition; DNA damage; Neuron; Neurotoxicity; Oxidative stress

Mesh:

Year:  2021        PMID: 34363676      PMCID: PMC8660580          DOI: 10.1093/jnen/nlab074

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  60 in total

Review 1.  Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness.

Authors:  Kenneth A Conklin
Journal:  Integr Cancer Ther       Date:  2004-12       Impact factor: 3.279

2.  Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy.

Authors:  Barbara Collins; Joyce Mackenzie; Giorgio A Tasca; Carole Scherling; Andra Smith
Journal:  J Int Neuropsychol Soc       Date:  2013-11-15       Impact factor: 2.892

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

Authors:  Vincent Koppelmans; Michiel B de Ruiter; Fedde van der Lijn; Willem Boogerd; Caroline Seynaeve; Aad van der Lugt; Henri Vrooman; Wiro J Niessen; Monique M B Breteler; Sanne B Schagen
Journal:  Breast Cancer Res Treat       Date:  2011-12-29       Impact factor: 4.872

5.  Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.

Authors:  Sabine Deprez; Frederic Amant; Ann Smeets; Ronald Peeters; Alexander Leemans; Wim Van Hecke; Judith S Verhoeven; Marie-Rose Christiaens; Joris Vandenberghe; Mathieu Vandenbulcke; Stefan Sunaert
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

6.  Prefrontal cortex and executive function impairments in primary breast cancer.

Authors:  Shelli R Kesler; Jamie S Kent; Ruth O'Hara
Journal:  Arch Neurol       Date:  2011-11

7.  Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study.

Authors:  Julie A Dumas; Jenna Makarewicz; Geoffrey J Schaubhut; Robert Devins; Kimberly Albert; Kim Dittus; Paul A Newhouse
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

8.  Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy.

Authors:  Lori-Ann Christie; Munjal M Acharya; Vipan K Parihar; Anna Nguyen; Vahan Martirosian; Charles L Limoli
Journal:  Clin Cancer Res       Date:  2012-02-14       Impact factor: 12.531

9.  Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy.

Authors:  Masatoshi Inagaki; Eisho Yoshikawa; Yutaka Matsuoka; Yuriko Sugawara; Tomohito Nakano; Tatsuo Akechi; Noriaki Wada; Shigeru Imoto; Koji Murakami; Yosuke Uchitomi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

10.  Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrain").

Authors:  Jeriel T R Keeney; Xiaojia Ren; Govind Warrier; Teresa Noel; David K Powell; Jennifer M Brelsfoard; Rukhsana Sultana; Kathryn E Saatman; Daret K St Clair; D Allan Butterfield
Journal:  Oncotarget       Date:  2018-07-13
View more
  1 in total

Review 1.  Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?

Authors:  Sanne B Schagen; Andrey S Tsvetkov; Annette Compter; Jeffrey S Wefel
Journal:  Nat Rev Neurol       Date:  2022-02-09       Impact factor: 44.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.